Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

Think about mental health and the impact of our Invega portfolio, Spravato, and the potential ... providing strategic near- and long-term growth catalysts for Johnson & Johnson.

Presentation Operator Good morning and welcome to Johnson and Johnson's fourth quarter 2024 earnings conference call. All ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

It has been used as a party drug for decades but is an “approved medical product as an injectable, short-acting anesthetic for use in humans and animals and as a nasal spray (Spravato ...

Though esketamine/Spravato is offered exclusively as a nasal ... On an anecdotal level, one patient recently told me that she often feels "the cord is cut" between her thoughts and her emotions ...

She told me that she didn’t know it was possible to feel this good, saying that it wasn’t until she took Spravato that she realized she didn’t have to walk in the fog anymore. Full Interview Summary: ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...